• Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
    • Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara Jr PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, on behalf of theGALAHAD investigators.
    • Lancet Oncol. 2022 Feb 4:S1470-2045(21)00757-9. doi: 10.1016/S1470-2045(21)00757-9. Epub ahead of print.